Discover Great Companies Discover Great Clients
Companies Salaries Jobs
Jobs |
Jobs Companies Salary Majors

Company Overview

Development Stage

About the Company

智康博药是Cothera Bioscience的医药研发子公司,专注于抗肿瘤药物研发领域及肿瘤个体化精准医疗服务。自2012年成立至今,已经拥有了体内、体外的转化医学研究平台,具有实战经验和全球化的管理和科研团队,丰富的产品管线和稳固的合作伙伴。公司先后获得国家高新技术企业、北京市科技研究开发机构、中关村高新技术企业等多项资质与荣誉
董事长吴越和科学家陈一友博士是原北京中美冠科生物技术有限的创始人,他们带领30多名开发科技人员,自主研发了全新的i-CR®肿瘤原代细胞体外药物筛选平台。并在合成致死 (synthetic lethality) 和免疫治疗领域开发出针对癌症的一系列新药产品线, 前期研发成果已经申请了多项国际和国内专利, 部分产品已经在国内外准备开展临床研究。

Expand
Information is aggregated from the web and may not be exact. For reference only.
Information incorrect? Claim this company to edit

智康博药 Financing History (2 rounds)

Manage
B轮
Capital Market Favor
Latest Financing Round
  • Date: ?
  • Amount: 融资金额未公开
  • Investor: 磐霖资本

智康博药 honors, qualifications & industry associations

智康博药 Related Industry Tags

Business Registration

Provided by

Operating Status: 开业
Registered Capital: 10,184.2963万(元)
Legal Representative: 吴越(YUE ALEXANDER WU)
Date Established:
Credit Code: 91110114057392914Y
Registered Address: 北京市昌平区科技园区生命园路8号院11号楼5层

Report

*Reason:

Radical political or ideological topics
Advertising or spam
Pornographic or vulgar content
Obscene language or personal attacks
Other

Congratulations, submitted successfully!

Your edit is under review. You will be notified by email within 1 business day.

Submission failed.

Followed successfully. We'll notify you of any company updates.

Help others learn about this company, add my impression of this company»

Log in with the following accounts to save your follows

Followed successfully, we'll notify you of any company updates

生活服务-综合平台
客服
由百度提供